Electronic Supplementary Material: Online Resource 3


International Journal of Clinical Oncology


Real-world analysis of treatment sequencing and late-stage liquid biopsy genomic profiling in advanced pancreatic cancer


Naohiro Nishida, Eisuke Iwasaki, Ken-Ichi Okada


Corresponding author: Naohiro Nishida
Department of Clinical Oncology, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa 259-1193, Japan
E-mail: nnishida@tokai.ac.jp


Online Resource 3. Kaplan–Meier survival curves comparing patients according to the presence or absence of each biomarker (Figure legends in the next page)




















(a–g) Kaplan–Meier survival curves comparing patients according to the presence or absence of each biomarker: fusion genes (ALK, FGFR2, NTRK, RET, and ROS1) (a), MSI-high status (b), TMB-high defined as ≥10 mutations/Mb (c), TMB-high defined as ≥20 (d), BRCA1/BRCA2 mutations (e), BRAF V600E mutation (f), and ERBB2 amplification (g).

(h) Kaplan–Meier survival curves stratified into four groups according to combined MSI status (MSI-high vs. non–MSI-high) and TMB status (TMB-high ≥10 mutations/Mb vs. non–TMB-high). The color and corresponding group designation for each survival curve are indicated within the figure.